Novartis settles Chinese bribery charges with $25M payment
The SEC says Novartis has settled civil charges of committing bribery in China and agreed to pay $25M to the government. Violations happened from 2009 to 2013, the SEC says; Novartis' settlement means that it doesn't admit or deny the charges, and it says the allegations largely predate compliance measures that are now in place.
from Biotech News
0 Comments